What are the median Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) levels in patients infected with Epstein-Barr Virus (EBV)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

The median AST and ALT levels in Epstein-Barr virus (EBV) infection are increased by an average maximum of 5-fold, with both transaminase levels starting to rise 2 days after the clinical onset of the disease and returning to normal after a period of 20 days 1. During acute EBV infection (infectious mononucleosis), liver enzyme elevations are common, occurring in approximately 80-90% of patients. These elevations usually develop within the first two weeks of illness and gradually normalize over 3-4 weeks as the infection resolves. The liver enzyme elevation pattern in EBV typically shows AST and ALT rising in parallel, with values rarely exceeding 10 times the upper limit of normal. This transient hepatitis is caused by the immune response to EBV-infected lymphocytes in the liver rather than direct viral infection of hepatocytes. While these enzyme elevations indicate liver involvement, they rarely progress to severe hepatitis or liver failure in immunocompetent individuals. No specific treatment is required for the hepatitis component of EBV infection beyond supportive care and monitoring of liver function until resolution. Some studies have reported rare cases of life-threatening jaundice and hepatic failure in patients with EBV infection, but these cases are extremely rare and often require a multidisciplinary approach for diagnosis and treatment 2. Other studies have investigated the use of steroids for symptom control in infectious mononucleosis, but the evidence is limited and inconclusive 3. Overall, the management of EBV infection should focus on supportive care and monitoring of liver function, with rare cases requiring more aggressive treatment. Key points to consider include:

  • The median AST and ALT levels in EBV infection are increased by an average maximum of 5-fold 1
  • Liver enzyme elevations are common in EBV infection, but rarely progress to severe hepatitis or liver failure 1
  • The liver enzyme elevation pattern in EBV typically shows AST and ALT rising in parallel, with values rarely exceeding 10 times the upper limit of normal 1
  • No specific treatment is required for the hepatitis component of EBV infection beyond supportive care and monitoring of liver function until resolution 1

References

Research

Epstein Barr virus hepatitis.

European journal of internal medicine, 2011

Research

Steroids for symptom control in infectious mononucleosis.

The Cochrane database of systematic reviews, 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.